Changes in renal function following nedaplatin‑containing chemotherapy in patients with urothelial carcinoma unfit for cisplatin

Introduction

Systematic chemotherapy has been the mainstay of treatment for advanced urothelial carcinoma (UC). Cisplatin-containing combination therapy is considered as standard first-line chemotherapy. However, many patients with advanced UC have renal dysfunction and poor performance status (1). Due to the nephrotoxicity and gastrointestinal toxicity associated with cisplatin, many patients are often unfit for drug treatment, with the proportion in various cohorts ranging from 30–60% (2,3). Carboplatin is frequently substituted for cisplatin, although its therapeutic efficacy is reportedly inferior to that of cisplatin (4). To date, no standard therapy for cisplatin-unfit patients has been established.

Nedaplatin is a platinum derivative that was developed in Japan. It is more soluble than cisplatin, and has less side effects in terms of renal function and gastrointestinal symptoms (5). Nedaplatin has antitumor activity in various cancer types, such as head and neck cancer, lung cancer, cervical cancer, and ovarian cancer. In advanced UC, the response rate with nedaplatin alone is 28.6%. In terms of renal toxicity, serum creatinine elevation is observed in 15.1% of the patients (6). However, the anticancer effect and the impact on renal function of nedaplatin is poorly understood when it is included as part of a combination regimen in UC.

To determine the extent of renal toxicity associated with nedaplatin-containing combination chemotherapy, we designed the current study to evaluate changes in renal function of nedaplatin combination regimens in patients with advanced UC.

Materials and methods

Patients

A total of 35 UC patients who had received nedaplatin-containing chemotherapy at the Shiga University of Medical Science Hospital from 2001 to 2014 were studied retrospectively. As comparative controls, we also examined 35 patients with the same disease who underwent cisplatin-containing chemotherapy during the same period. The eligibility criteria were as follows 1): UC with local invasion or metastasis, 2) cisplatin ineligible due to impaired renal function, 3) cisplatin-related adverse events during previous chemotherapy, and 4) an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. In our institution, a cutoff value of measured creatinine clearance <60 ml/min was used to exclude patients from receiving cisplatin-containing chemotherapy.

The present study was approved by the ethics review board of Shiga University of Medical Science (Shiga, Japan).

Nedaplatin-containing regimens and treatment schedule

Cisplatin was replaced with nedaplatin in select combination regimens. Two regimens were performed. One was methotrexate/epirubicin/nedaplatin (MEN) therapy, which is essentially a modified version of methotrexate/epirubicin/cisplatin (MEC) therapy (7). The other was gemcitabine/nedaplatin (GN) therapy, which was based on a modification of gemcitabine/cisplatin (GC) therapy (8). Patients who were given MEN therapy received methotrexate (30 mg/m2) on days 1 and 15, epirubicin (50 mg/m2) on day 1 and nedaplatin (80 mg/m2) on day 2 intravenously (Fig. 1). Patients given GN therapy received gemcitabine (1,000 mg/m2) on days 1, 8 and 15 and nedaplatin (80 mg/m2) on day 1 intravenously. Both regimens were repeated every 4 weeks. Physicians reduced the dose of nedaplatin based on the occurrence of severe hematologic toxicity and/or compromised renal function.

Figure 1. Treatment scheme of the nedaplatin combination regimen. MEN, methotrexate/epirubicin/nedaplatin therapy; GN, gemcitabine/nedaplatin therapy.

Evaluation of renal function and therapeutic effect

We compared estimated glomerular filtration rate (eGFR; ml/min/1.73 m2) before and after each cycle of chemotherapy. The eGFR after administration was assessed just before the next cycle, and was calculated using the following formula reported by the Japanese Society of Nephrology in 2008. eGFR=194×Cr−1.094xAge−0.287 if male, or 194×Cr−1.094xAge0.739 if female (9).

Therapeutic effects were evaluated using the response rate according to the Response Evaluation Criteria in Solid Tumors (10). Toxicity was monitored according to Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.

Statistical analysis

Differences between patients' characteristics were estimated using a chi-square test and an independent sample t test. Paired t tests were used to compare changes of eGFR between pre- and post-administration in each cycle of chemotherapy. All data were analyzed using SPSS software (v.22; IBM Corp., Armonk, NY, USA) and P<0.05 was considered to indicate a statistically significant difference.

Results

Patients' characteristics

Patients' characteristics are shown in Table I. The primary tumors in both groups were four cases of renal pelvic carcinoma (11%), 13 cases of ureter carcinoma (37%) and 18 cases of bladder carcinoma (51%). The median ages of patients who underwent nedaplatin combination regimen (nedaplatin group) and cisplatin combination regimen (cisplatin group) were 64 and 68 years, respectively; this difference was not statistically significant. On the other hand, the performance status was significantly poorer in the nedaplatin group than in the cisplatin group.

Table I. Patients' characteristics.

Table I.

Patients' characteristics.

Characteristic	Cisplatin group	Nedaplatin group	P-value
Age (years)			0.052
Median	68	64
Range	55–82	54–83
Sex (n)			0.78
Male	26	27
Female	9	8
ECOG Performance status (n)			0.02a
0	15	8
1	20	20
2	0	7
Primary site (n)			1
Upper urinary tract	17	17
Bladder	18	18
Purpose of chemotherapy (n)			0.15
Neoadjuvant	10	5
Adjuvant	10	16
Metastasis	25	18
Prior chemotherapy, n (cycles)
None		17
MEC		13 (21)
GC		9 (36)
Regimen (cycles)
MEC	24	66
GC/GN	145	31

a P<0.05. MEN, methotrexate/epirubicin/nedaplatin therapy; GN, gemcitabine/nedaplatin therapy; GC, gemcitabine/cisplatin therapy; ECOG, Eastern Cooperative Oncology Group.

All patients of the cisplatin group and 97% (34 of 35) of the nedaplatin group received these drugs as first-line therapy. In the nedaplatin group, approximately half of patients had received a prior cisplatin combination regimen (57%) and were switched to nedaplatin due to cisplatin-unfitness. Only one case was treated as the second-line therapy for relapse after a prior cisplatin combination regimen.

Patients treated with the nedaplatin combination regimen underwent 66 cycles of MEN therapy and 31 cycles of GN therapy. The most common reason for using nedaplatin was chronic renal failure (18 cases, 51%); the second was impaired renal function caused by the cisplatin combination regimen (13 cases, 37%). Twenty-four patients had an eGFR of 30–60 ml/min/1.73 m2, and four patients had an eGFR of less than 30 ml/min/1.73 m2 before induction of nedaplatin chemotherapy.

Changes in renal function before and after chemotherapy

We compared changes in eGFR at each cycle of chemotherapy (Fig. 2). In the nedaplatin group (n=97 cycles), the mean eGFRs before and after chemotherapy were 45.4 ml/min/1.73 m2 and 47.8 ml/min/1.73 m2, respectively. The post-chemotherapy eGFR was significantly increased (P<0.001). The eGFR in the nedaplatin group was significantly elevated, even when cases with eGFR <60 ml/min/1.73 m2 were analyzed (n=87 cycles). On the other hand, in the cisplatin group (n=169 cycles), the mean eGFRs before and after chemotherapy were 51.0 ml/min/1.73 m2 and 48.5 ml/min/1.73 m2, respectively. This decrease was statistically significant (P<0.001). As a sub-analysis in the nedaplatin group, eGFR alterations in patients whose renal function was impaired by prior cisplatin administration were investigated (n=33 cycles in 13 patients). No decrease in renal function following nedaplatin administration was observed in this sub-population (Fig. 3). In a subgroup of patients where nedaplatin dose reduction was not required, the mean eGFR values before and after chemotherapy were 59.2 ml/min/1.73 m2 and 63.2 ml/min/1.73 m2, respectively (n=16 cycles in 11 patients). Thus, renal function was not compromised in patients receiving the standard full dose of nedaplatin.

Figure 2. Changes in renal function associated with chemotherapy in the nedaplatin and cisplatin groups. *P<0.05 and **P<0.01, as indicated. SD, standard deviation; Pre, pre-chemotherapy; Post, post-chemotherapy.

Figure 3. Changes in renal function associated with nedaplatin administration in patients who had experienced kidney injury following the previous administration of cisplatin combination therapy (n=33 cycles). *P<0.05, as indicated. SD, standard deviation.

Treatment evaluation

In the nedaplatin group, the median number of times the nedaplatin combination regimens administered was two cycles (1–8 cycles, Table II). The median dose of nedaplatin per cycle was 60.0 mg/m2, and the median relative dose intensity (RDI) was 63.0%. In the cisplatin group, RDI and number of chemotherapy cycles were significantly larger than in the nedaplatin group (P<0.001). Of the 23 patients who had measurable lesions in the nedaplatin group, one complete response (CR) (4.3%) and six partial responses (PRs) (26.1%) were observed. The overall response rate (CR+PR) was 30.4% in the nedaplatin group, and 66.7% in the cisplatin group. The overall response rate of all cases and metastatic cases was higher in the cisplatin group than in the nedaplatin group (P<0.001). In the nedaplatin group, the overall response rates in patients with and without prior cisplatin chemotherapy were 23.1% (3 of 13 cases) and 40.0% (4 of 10 cases), respectively.

Table II. Amount of treatment and best overall response.

Table II.

Amount of treatment and best overall response.

Variable	Cisplatin group	Nedaplatin group	P-value
Relative dose intensity (%)
Median	96.3	63
Range	50–100	34.5–143.0	0.0004b
Number of cycle (cycles)
Median	4	2
Range	1–13	1–8	0.0008b
Overall response rate, % (n)
All cases	66.7 (20)	30.4 (7)	0.0090a
Metastatic cases	65 (13)	22.2 (4)	0.0080a
Neoadjuvant chemotherapy cases	70 (7)	60 (3)	0.7000

a P<0.01

b P<0.001.

Adverse events

In both groups, myelosuppression was the most common side effect (Table III). Leucopenia of Grade 3 or more was observed in 68.6 and 65.7% in the cisplatin and nedaplatin groups, respectively. The incidence of febrile neutropenia also occurred at frequencies of 20.0 and 22.9% in the cisplatin and nedaplatin groups, respectively. The incidences of Grade 2 and 3 acute kidney injuries were 8.6% (3 patients) and 2.9% (1 patient) in the cisplatin group, whereas in the nedaplatin group there was no acute kidney injury of Grade 2 or higher. The frequency of gastrointestinal side effects such as anorexia was lower in the nedaplatin group than in the cisplatin group, although this difference was not statistically significant.

Table III. Adverse Events (Common Terminology Criteria for Adverse Events version 4.0, Grade 3 and above).

Table III.

Adverse Events (Common Terminology Criteria for Adverse Events version 4.0, Grade 3 and above).

	Cisplatin group		Nedaplatin group
Adverse event	No.	%	No.	%	P-value
Myelosuppression
Anemia	17	48.6	18	51.4	0.810
Leukopenia	24	68.6	23	65.7	0.800
Thrombocytopenia	25	71.4	17	48.6	0.051
Febrile neutropenia	7	20.0	8	22.9	0.770
Nausea	0	0	1	2.9	0.310
Anorexia	5	14.3	1	2.9	0.088
Oral mucositis	0	0	1	2.9	0.310
Colonic obstruction	1	2.9	0	0	0.310
Acute kidney injury	1	2.9	0	0	0.310

Discussion

Cisplatin combination chemotherapy is a standard treatment for advanced UC. However, many patients with advanced UC are unfit for cisplatin therapy, and standard treatments for such patients have not been established. The proportion of cisplatin-unfit patients due to renal impairment is 28% in patients with advanced bladder cancer. In upper urinary tract cancer, 51 and 81% of patients had renal dysfunction before and after nephroureterectomy (2,3). For cisplatin-unfit patients, EAU guidelines recommend carboplatin combination regimens, and particular those that incorporate gemcitabine (11). However, the overall response rate of gemcitabine and carboplatin combination therapy for cisplatin-unfit metastatic UC is reported as 42%, and antitumor efficacy is limited (1).

Nedaplatin was developed in Japan to provide a treatment with a similar efficacy to cisplatin, but with less renal and gastrointestinal toxicities (5). Nedaplatin is approximately 10-fold more water-soluble than cisplatin, and this in part explains its reduced nephrotoxicity. Nedaplatin combination therapy elicited less nephrotoxicity than did cisplatin combination therapy. In the present study, no decrease in eGFR was observed after administration of the nedaplatin combination regimen; rather, eGFR was significantly increased. Similar renal function changes were found not only in the cases with eGFR <60 ml/min/1.73 m2, but also in the case with renal failure due to previous cisplatin chemotherapy. On the other hand, the cisplatin combined regimen reduced eGFR, indicating that nedaplatin is less nephrotoxic compared to cisplatin, and thus safe to use in patients with renal impairment. Regarding the increase of eGFR in the nedaplatin group, it is unlikely that nedaplatin itself had a positive effect on renal function. There were three cases in which hydronephrosis was improved due to the therapeutic effect of nedaplatin, and cases who had improved renal function over time after acute renal failure following cisplatin administration. We infer that these cases affected the significant increase in eGFR after nedaplatin combination regimen.

In the present study, the overall response rate was lower than that observed in other reports of nedaplatin (Table IV) (6,12–14). This may be due to a difference in the drugs that were used in combination with nedaplatin. We currently use gemcitabine in combination with nedaplatin, because an in vivo study suggested a synergistic inhibition of lung cancer cell growth using this combination (15). However, it is unknown whether synergy between nedaplatin and gemcitabine would also be observed in UC. In a meta-analysis of non-small cell lung cancer, docetaxel or paclitaxel plus nedaplatin produced a longer overall and progression-free survival than gemcitabine plus nedaplatin (16). In other studies, nedaplatin was used in combination with paclitaxel to treat UC (12,13), which is different from the combinations used in our regimens. We note that patients with lymph node metastasis alone are generally more responsive to anticancer drugs than patients with visceral metastases. Our study had fewer cases with lymph node metastasis alone, which may have masked any association between this disease stage and treatment efficacy. Thirdly, 57% of patients in our nedaplatin group had previously received treatment with a cisplatin combination regimen. Nedaplatin has the same amine carrier ligand as cisplatin, binds to DNA, and inhibits DNA replication and transcription in a similar manner to cisplatin. Therefore, cross-resistance to nedaplatin can be induced by prior cisplatin treatment (5), and in this study the overall response rate of patients after a cisplatin containing regimen was as low as 23.1%. Finally, a low median dose of 60.0 mg/m2 may lead to a decrease in response rate, although the nedaplatin setting dose is 80.0 mg/m2.

Table IV. Clinical trials of nedaplatin regimen in patients with urothelial carcinoma.

Table IV.

Clinical trials of nedaplatin regimen in patients with urothelial carcinoma.

Author, year	No. of patients	No. of patients with prior chemotherapy	Regimen	Dose of nedaplatin (mg/m2)	Overall response rate (%)	Lymph node metastases alone/lymph node and other metastases (%)	(Refs.)
Akaza et al, 1992	35	13	Nedaplatin	100	28.6	NA/34.3	(6)
Shinohara et al, 2006	32	32	Nedaplatin, Paclitaxel, Ifosfamide	70	75.0	50/75	(12)
Kitamura et al, 2011	45	45	Nedaplatin, Paclitaxel, Ifosfamide	70	40.0	42.2/68.9	(13)
Umemoto et al, 2007	12	10	GN	80	41.7	NA/50	(14)
Present study	23	13	MEN, GN	80	30.4	27.8/66.7	–

[i] NA, not available; MEN, methotrexate/epirubicin/nedaplatin therapy; GN, gemcitabine/nedaplatin therapy.

There was no significant difference in the incidence of adverse events induced by cisplatin and nedaplatin. Among the adverse events, the frequency of bone marrow suppression was the highest. Some patients developed febrile neutropenia and required platelet transfusions, but these adverse events were manageable in both groups.

There are some limitations in our study. First, it is a retrospective analysis, and the RDI of the nedaplatin group was low. Therefore, the apparent antitumor efficacy of nedaplatin is comparatively weak. Second, our data were obtained from a small number of patients at a single institution. Third, carboplatin-containing chemotherapy is the most used for cisplatin-unfit patients, but there has been no study comparing the efficacy of carboplatin with that of nedaplatin. We therefore propose that future prospective studies should directly compare the efficacy and safety of nedaplatin and carboplatin.

In conclusion, nedaplatin-containing chemotherapy for cisplatin-unfit patients with advanced UC can be performed safely and is not associated with renal toxicity. Nedaplatin-containing chemotherapy may be available for cisplatin-unfit patients with cancer types other than UC. In order to optimize the use of nedaplatin as an alternative to cisplatin, the optimal drug combinations and the appropriate dose setting of nedaplatin should be elucidated in order to improve its antitumor effect.

Acknowledgements

Not applicable.

Funding

The present study was supported in part by a Grant in Aid for Young Scientists (B) from JSPS KAKENHI (grant no. 17K16787).

Availability of data and material

The data generated during the current study are available from the corresponding author on reasonable request.

Authors' contributions

MaN, SuK and AK conceived and designed the present study. MaN, TY, YO, ShK, AW, KT, KK, RM and TT obtained the patients' data and performed experiments/evaluations. MaN, SuK, KJ and MiN analyzed and interpreted the data. MaN and SuK drafted the manuscript. SuK, KJ, MiN and AK revised the manuscript. SuK and AK supervised the study. MaN acquired funding. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the ethics review board of Shiga University of Medical Science (Shiga, Japan) and was performed in accordance with the Declaration of Helsinki.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References